Safe injection practices minimize risk of injuries, infections, and non-infectious adverse events for both patients and providers. The deltoid muscle over the triceps area of the upper arm is preferred for persons 3 years of age and older. The appropriate site for an intramuscular injection for those under 2 years of age is the vastus lateralis muscle. A needle is used to inject the vaccine into the muscle. Intramuscular (IM) Injection: Sites: This training helps providers identify intramuscular (IM) injection sites.Administering More Than One Vaccine on the Same Day: Clinical Considerations.Vaccine Administration: Needle Gauge and Length.Vaccine Administration: Intramuscular (IM) Injection Children 7 through 18 years of age.Vaccine Administration: Intramuscular (IM) Injection Children 3 through 6 years of age.Vaccine Administration: Intramuscular (IM) Injection Children 1 through 2 years of age.Vaccine Administration: Intramuscular (IM) Injection Infants 11 months of age and younger.General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP).“Vaccine Administration” chapter, Epidemiology and Prevention of Vaccine-Preventable Diseases(the Pink Book)-includes pictures of vaccine administration sites.COVID-19 Vaccine Product Information: Find a suite of information and materials needed for each specific COVID-19 vaccine that covers administration, storage and handling, safety, and reporting.
Training and Education for COVID-19 Vaccination. Coronavirus (COVID-19) Update: FDA Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine for Children 6 Months Through 4 Years of Age | FDAĬlinical Training and Education for Vaccinators. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020–August 14, 2021(CDC, MMWR). Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years - United States, August 2020–August 2021(CDC, MMWR). Characteristics and Clinical Outcomes of Children and Adolescents Aged 18 Years Hospitalized with COVID-19 - Six Hospitals, United States, July–August 2021 | MMWR (cdc.gov). COVID-19 Vaccine Safety in Children Aged 5–11 Years - United States, November 3–Decem| MMWR (cdc.gov). Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years - VISION Network, 10 States, April 2021–January 2022 (CDC, MMWR). Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years - United States, December 9, 2021–Febru(CDC, MMWR). Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years - PROTECT Cohort, July 2021–February 2022 (CDC, MMWR). Children and COVID-19: State Level Data Report (American Academy of Pediatrics and the Children’s Hospital Association). Provisional COVID-19 Deaths: Focus on Ages 0-18 Years (National Center for Health Statistics). 
COVID-Net State Activity Indicator Map (U.S.CDC COVID Data Tracker (Pediatric Data).
0 kommentar(er)
